X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs DISHMAN PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA DISHMAN PHARMA GSK PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 68.6 25.1 273.6% View Chart
P/BV x 13.8 3.3 412.8% View Chart
Dividend Yield % 1.0 0.7 157.0%  

Financials

 GSK PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
DISHMAN PHARMA
Mar-16
GSK PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,760374 737.2%   
Low Rs2,040129 1,582.6%   
Sales per share (Unadj.) Rs339.0197.8 171.4%  
Earnings per share (Unadj.) Rs41.421.2 195.3%  
Cash flow per share (Unadj.) Rs45.934.7 132.2%  
Dividends per share (Unadj.) Rs35.002.00 1,750.0%  
Dividend yield (eoy) %1.50.8 183.5%  
Book value per share (Unadj.) Rs242.9179.9 135.0%  
Shares outstanding (eoy) m84.7080.69 105.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.11.3 556.4%   
Avg P/E ratio x57.911.9 488.3%  
P/CF ratio (eoy) x52.37.2 721.4%  
Price / Book Value ratio x9.91.4 706.3%  
Dividend payout %84.59.4 896.0%   
Avg Mkt Cap Rs m203,28020,306 1,001.1%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m5,2345,355 97.7%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m28,71515,961 179.9%  
Other income Rs m545265 205.5%   
Total revenues Rs m29,26016,226 180.3%   
Gross profit Rs m5,0594,103 123.3%  
Depreciation Rs m3801,091 34.8%   
Interest Rs m2944 0.2%   
Profit before tax Rs m5,2222,334 223.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,892624 303.4%   
Profit after tax Rs m3,5081,711 205.0%  
Gross profit margin %17.625.7 68.5%  
Effective tax rate %36.226.7 135.6%   
Net profit margin %12.210.7 114.0%  
BALANCE SHEET DATA
Current assets Rs m21,81511,018 198.0%   
Current liabilities Rs m15,9999,517 168.1%   
Net working cap to sales %20.39.4 215.4%  
Current ratio x1.41.2 117.8%  
Inventory Days Days64110 57.5%  
Debtors Days Days1935 53.6%  
Net fixed assets Rs m12,47516,304 76.5%   
Share capital Rs m847161 524.8%   
"Free" reserves Rs m19,72612,907 152.8%   
Net worth Rs m20,57314,516 141.7%   
Long term debt Rs m64,189 0.1%   
Total assets Rs m39,47529,805 132.4%  
Interest coverage x2,612.03.5 75,252.4%   
Debt to equity ratio x00.3 0.1%  
Sales to assets ratio x0.70.5 135.8%   
Return on assets %8.98.9 99.8%  
Return on equity %17.111.8 144.6%  
Return on capital %26.217.5 149.7%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m5644,952 11.4%   
Fx outflow Rs m7,429697 1,066.2%   
Net fx Rs m-6,8654,255 -161.4%   
CASH FLOW
From Operations Rs m4,7282,786 169.7%  
From Investments Rs m-1,042-1,529 68.1%  
From Financial Activity Rs m-3,066-941 325.8%  
Net Cashflow Rs m620316 195.9%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 3.7 275.7%  
FIIs % 23.8 12.7 187.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 22.1 69.7%  
Shareholders   102,036 46,261 220.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  PLETHICO PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Energy and Metal Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours of trade and ended the day at their fresh record high levels.

Related Views on News

DIVIS LABORATORIES at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

Aug 20, 2018 | Updated on Aug 20, 2018

DIVIS LABORATORIES share price has hit a 52-week high. It is presently trading at Rs 1,224. BSE 500 Index is up by 0.5% at 15,582. Within the BSE 500, DIVIS LABORATORIES (up 4.3%) and KWALITY DAIRY (up 5.0%) are among the top gainers, while top losers are TECHNO ELECTRIC and RAIN INDUSTRIES.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 20, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS